Fluticasone detailed information

Fluticasone detailed information

Clinical data
Pregnancy category	C for Intranasal and Inhaled
Routes of administration	Intranasal, Inhaled, Topical Cream or Ointment
ATC code	D07AC17 (WHO) & D07AC04 (WHO) topical, R01AD08 (WHO) nasal, R03BA05 (WHO) inhaled
Legal status
Legal status	UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	0.51% (Intranasal)
Protein binding	91%
Metabolism	Intranasal Hepatic (CYP3A4-mediated)
Elimination half-life	10 hours
Excretion	Renal
Identifiers
IUPAC name S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)- 6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo- 6,7,8,11,12,14,15,16-octahydrocyclopenta[a] phenanthrene-17-carbothioate
CAS Number	80474-14-2
PubChem CID	5311101
DrugBank	APRD00065
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C22H27F3O4S
Molar mass	444.508 g/mol

WikiDoc Resources for Fluticasone detailed information
Articles
Most recent articles on Fluticasone detailed information Most cited articles on Fluticasone detailed information Review articles on Fluticasone detailed information Articles on Fluticasone detailed information in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Fluticasone detailed information Images of Fluticasone detailed information Photos of Fluticasone detailed information Podcasts & MP3s on Fluticasone detailed information Videos on Fluticasone detailed information
Evidence Based Medicine
Cochrane Collaboration on Fluticasone detailed information Bandolier on Fluticasone detailed information TRIP on Fluticasone detailed information
Clinical Trials
Ongoing Trials on Fluticasone detailed information at Clinical Trials.gov Trial results on Fluticasone detailed information Clinical Trials on Fluticasone detailed information at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Fluticasone detailed information NICE Guidance on Fluticasone detailed information NHS PRODIGY Guidance FDA on Fluticasone detailed information CDC on Fluticasone detailed information
Books
Books on Fluticasone detailed information
News
Fluticasone detailed information in the news Be alerted to news on Fluticasone detailed information News trends on Fluticasone detailed information
Commentary
Blogs on Fluticasone detailed information
Definitions
Definitions of Fluticasone detailed information
Patient Resources / Community
Patient resources on Fluticasone detailed information Discussion groups on Fluticasone detailed information Patient Handouts on Fluticasone detailed information Directions to Hospitals Treating Fluticasone detailed information Risk calculators and risk factors for Fluticasone detailed information
Healthcare Provider Resources
Symptoms of Fluticasone detailed information Causes & Risk Factors for Fluticasone detailed information Diagnostic studies for Fluticasone detailed information Treatment of Fluticasone detailed information
Continuing Medical Education (CME)
CME Programs on Fluticasone detailed information
International
Fluticasone detailed information en Espanol Fluticasone detailed information en Francais
Business
Fluticasone detailed information in the Marketplace Patents on Fluticasone detailed information
Experimental / Informatics
List of terms related to Fluticasone detailed information

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Fluticasone propionate is a potent synthetic corticosteroid often prescribed as treatment for asthma and allergic rhinitis. It is marketed with the brand names Flixotide and Flixonase by Allen & Hanburys, and Flovent, and Flonase by GlaxoSmithKline. GlaxoSmithKline also markets a combination of fluticasone and salmeterol as Advair (US) or Seretide (UK).

It is also used as a cream or ointment for the treatment of eczema and psoriasis (Cutivate UK).

How it works

Inflammation is recognized as an important component in the pathogenesis of asthma. Glucocorticoids have been shown to inhibit multiple cell types (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and mediator production or secretion (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in the asthmatic response. These anti-inflammatory actions of glucocorticoids may contribute to their efficacy in asthma. Typically, however, the action on the cells affected requires several days. Therefore, inhaled steroids are not used for immediate relief of asthma, but instead as preventive and maintenance therapy.

Nasal spray

Dosage

• Adults: The recommended dosage for adults is 100 micrograms (two sprays) into each nostril once daily. This may be increased to maximum of twice daily use if required. When control is achieved dose is reduced to 50 micrograms (one spray) to each nostril daily.

A canister of Flovent in the inhaler.

• Adolescents and children: The recommended dosage for children (4 years of age or older in US, but only from 12 years in UK) is 50 micrograms (one spray) into each nostril once daily. This may be increased to maximum of twice daily use if required.

Flonase patent issues

GlaxoSmithKline's patent on Flonase expired in May 2004. The Food and Drug Administration (FDA) approved the sale of a generic version of Flonase on February 22, 2006. On February 23, 2006, GlaxoSmithKline (GSK) was able to obtain a temporary 10-day restraining order from a federal judge in Baltimore blocking the shipment and sales of the approved generic versions of Flonase. The restraining order lasted until March 6, 2006. The basis of the complaint by GSK was that the FDA failed to follow its own regulations in approving the generics and failed to apply the same quality standards for the generic version as it did for Flonase. GSK made these arguments in petitions filed with the FDA, but the FDA rejected those petitions. The Maryland District Court denied the request by GSK to extend the ban on Flonase generics beyond March 6, 2006, and GSK released a statement that they would not appeal the ruling.[2] The ruling meant that sales of generic versions of Flonase could proceed.

References

• GSK's official statement on Flonase generic
• RxList The Internet Drug Index
• BNF 45 March 2003

Clinical trials

This listing is NOT complete and should NOT be construed as support for treatment decisions. See also PubMed clinical manuscripts referring to fluticasone

• Burge P, Calverley P, Jones P, Spencer S, Anderson J, Maslen T (2000). "Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial". BMJ. 320 (7245): 1297–303. PMID 10807619.CS1 maint: Multiple names: authors list (link)
• Paggiaro P, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J (1998). "Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group". Lancet. 351 (9105): 773–80. PMID 9519948.CS1 maint: Multiple names: authors list (link)

both support a positive outcome for use of fluticasone in patients with chronic obstructive pulmonary disease, also referred to as COPD

External link

• Flixonase Official Website

Template:WikiDoc Sources hu:Flutikazon